Avastin fails stomach-cancer trial
Roche got a big disappointment today: The cancer drug Avastin failed a clinical trial in stomach cancer, one of the new indications the drugmaker had been aiming for. The company had predicted sales for stomach-cancer patients could have reached as high as 1 billion Swiss francs, or $933 million. Here’s the scoop: Avastin failed to meet its primary target of extending overall survival in patients using it in combination with chemotherapy, compared with patients on a combo of placebo and chemotherapy, Roche says.
